Health Canada authorizes Cytokinetics’ MYQORZO for adult obstructive hypertrophic cardiomyopathy
Cytokinetics announced that Health Canada issued a Notice of Compliance for MYQORZO® (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults with NYHA class II‑III disease. The approval marks the drug’s fifth regulatory clearance worldwide after the United States, China, the European Union and the United Kingdom. The decision was based on the Phase 3 SEQUOIA‑HCM trial, which showed a 1.76 mL/kg/min increase in peak oxygen uptake versus placebo.
Why it matters
The company said the Canadian launch, pricing and reimbursement schedule will be a new catalyst for revenue growth. Analysts note that the approval expands the market footprint of MYQORZO, potentially adding sales in Canada once the product is launched.
Key facts
- 1Health Canada issued a Notice of Compliance authorizing MYQORZO for adult NYHA class II‑III oHCM on Oct. 19 2026. stocktitan.net
- 2MYQORZO is a once‑daily oral allosteric and reversible cardiac myosin inhibitor. stocktitan.net
- 3The approval is the fifth for MYQORZO in less than a year, following the United States, China, European Union and United Kingdom. stocktitan.net
- 4The SEQUOIA‑HCM Phase 3 trial showed a 1.76 mL/kg/min increase in peak oxygen uptake (pVO₂) versus baseline, compared with 0.0 mL/kg/min for placebo. stocktitan.net
- 5Cytokinetics expects Canadian pricing, reimbursement and launch timing to become catalysts later in 2026. tradingview.com
- 6The stock rose 0.64% to $62.35 following the announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.